Which selective serotonin reuptake inhibitors are least likely to cause headache?

SSRIs and Headache Risk

Based on the available evidence, most SSRIs do not cause clinically significant headaches, and when headaches occur after starting an SSRI, they are more likely coincidental than treatment-related. The only SSRIs with statistically increased headache risk compared to placebo are bupropion and escitalopram, though bupropion is technically not an SSRI 1.

Evidence-Based Recommendations

Lowest Headache Risk SSRIs

If you need to avoid headache as a side effect, consider these options in order:

1. Sertraline - No significant headache risk identified in meta-analysis 1
2. Fluoxetine - No significant headache risk identified 1
3. Paroxetine - No significant headache risk identified 1
4. Fluvoxamine - No significant headache risk identified 1
5. Citalopram - No significant headache risk identified 1

SSRIs to Approach with Caution

• Escitalopram - The only true SSRI with statistically significant increased headache risk (RR = 1.18,95% CI = 1.01-1.37) 1
• Bupropion - Highest headache risk (RR = 1.22), though this is an NDRI, not an SSRI 1

Clinical Context

The 2018 meta-analysis examining second-generation antidepressants found that SSRIs as a class showed only a marginal increase in headache risk (RR = 1.06,95% CI = 1.00-1.13), barely reaching statistical significance 1. This minimal risk suggests that headaches reported after starting SSRIs are more likely coincidental than medication-induced.

Common SSRI Side Effects (Not Headache)

While headache is often listed as a potential side effect, the more consistently documented adverse effects across SSRIs include 2, 3:

• Gastrointestinal disturbances (nausea, diarrhea)
• Sexual dysfunction (particularly with paroxetine)
• Insomnia or sedation
• Activation/anxiety (especially during initiation)
• Weight changes

Notably, sertraline specifically has higher rates of diarrhea compared to other SSRIs, but not headache 4.

Important Caveats

Migraine Prevention Context

If the patient has comorbid migraines, the evidence is limited but noteworthy:

• Fluoxetine has limited evidence for modest migraine prevention effect at 20-40 mg/day 5
• No controlled trial evidence exists for fluvoxamine, paroxetine, or sertraline in migraine prevention 5
• Amitriptyline (a TCA, not SSRI) remains first-line for migraine prevention with consistent evidence 5

Discontinuation Syndrome

Paroxetine, fluvoxamine, and sertraline are associated with discontinuation syndrome when stopped abruptly, which can include headaches as a withdrawal symptom 6. This is distinct from treatment-emergent headaches.

Practical Algorithm

For patients concerned about headache:

1. Start with sertraline, fluoxetine, paroxetine, fluvoxamine, or citalopram - all have no significant headache association
2. Avoid escitalopram as first choice if headache is a primary concern
3. If patient has comorbid migraines, consider fluoxetine (dual potential benefit) or refer for migraine-specific prophylaxis
4. Begin at subtherapeutic "test dose" to minimize initial anxiety/activation 6
5. If headaches develop within first 2 weeks, they are likely coincidental or related to anxiety/activation rather than direct medication effect

The evidence strongly suggests that choosing an SSRI based on headache risk is largely unnecessary, as the class effect is minimal and most individual agents show no increased risk.